Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | CNR2 | P34972 | 6/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12477397 | 0.90 | MAPT (0.61) | MAPTCNR2CNR1TP53LMNA | |
| SCHEMBL12697339 | 0.86 | MAPT (0.51) | MAPTCNR2TP53HTTMEN1 | |
| SCHEMBL12697466 | 0.84 | CYP11B1 (0.48) | MAPTCNR1TP53HTTNPSR1 | |
| SCHEMBL12476629 | 0.83 | MAPT (0.43) | MAPTCNR2TP53LMNANPSR1 | |
| SCHEMBL12697442 | 0.80 | SMN1; SMN2 (0.49) | MAPTRAB9AHTTMEN1LMNA | |
| SCHEMBL31060229 | 0.78 | CNR2 (0.72) | MAPTCNR2CNR1TP53RAB9A | |
| SCHEMBL12476569 | 0.78 | MAPT (0.46) | MAPTCNR2CNR1TP53RAB9A | |
| SCHEMBL12476785 | 0.78 | CNR2 (0.72) | MAPTCNR2CNR1TP53RAB9A | |
| SCHEMBL12477450 | 0.78 | CNR2 (0.47) | MAPTCNR2CNR1TP53 | |
| SCHEMBL12477136 | 0.77 | CNR2 (0.72) | MAPTCNR2CNR1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | claimed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | claimed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012090177-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012090177-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | MAPT 2605/4885CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.